JT

Jeffrey Tong

Third Rock Ventures

Menlo Park, California

VC
Investor

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Education

Lists including Jeffrey

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Marea Therapeutics

Series B

Total Funding: $260M

Asher Bio

Series A

Total Funding: $220M

ARTBIO

Series A

Total Funding: $110M

Terremoto Biosciences

Series A

Total Funding: $250M

Septerna

Series A

Total Funding: $250M

Ambys Medicines

Series A

Total Funding: $110M

Takko

Seed

Total Funding: $4M

Work Experience

TR
Third Rock Ventures

2016

  • Partner

    2016

    Focused on building innovative companies to serve patients with significant unmet medical needs. ARTBIO - Board member Asher Biotherapeutics - Board member Candid Therapeutics - Board member Marea Therapeutics - Board member Maze Therapeutics - Board member Rapport Therapeutics (RAPP) - Board member Septerna - Chairman of the board Past companies: Ambys Medicines Nurix (NRIX) Terremoto Biosciences

D
Delinia

2016 - 2017

  • Executive Chairman of the Board

    2016 - 2017

    Served as Executive Chairman and Chairman through $35M Series A financing and subsequent acquisition by Celgene for $775M with $300M upfront.

Nora Therapeutics

2010 - 2016

  • Member of the Board of Directors

    2010 - 2016

  • President & CEO

    2010 - 2015

IP
Infinity Pharmaceuticals

2001 - 2010

  • Vice President, Corporate and Product Development

    2001 - 2010

M&
McKinsey & Company

2000 - 2001

  • Consultant

    2000 - 2001